We conducted a systematic review which aimed to provide a summary of current clinical evidence of the effectiveness of COVID‐19 vaccination in the immunocompromised population. Our findings demonstrated that immunocompromised patients remained at high risk of breakthrough infection and severe COVID‐19 outcomes compared with the general population. This demonstrated that vaccination does not offer an adequate level of protection in these groups, necessitating further measures such as Evusheld and further boosters.
All Keywords
【저자키워드】 Cancer, SARS‐CoV‐2, vaccine effectiveness, severe COVID‐19 outcomes,
【저자키워드】 Cancer, SARS‐CoV‐2, vaccine effectiveness, severe COVID‐19 outcomes,